Seeking Alpha

Boston Scientific (BSX -0.5%) slips into the red today, despite saying it's received CE Mark...

Boston Scientific (BSX -0.5%) slips into the red today, despite saying it's received CE Mark approval for the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, and is initiating its European market launch. The system is designed to provide physicians improved drug eluting stent performance for treating patients with coronary artery disease.
Comments (2)
  • $CLU
    , contributor
    Comments (208) | Send Message
     
    Maybe the market doesn't like the name "Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System".
    It doesn't seem to roll off the tongue.
    12 Feb 2013, 03:00 PM Reply Like
  • gaidys
    , contributor
    Comment (1) | Send Message
     
    Tha's ok as long as the cholesterol rolls off the stent.
    13 Feb 2013, 02:41 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector